MA42161A - Nanoparticules pour thérapie photodynamique, thérapie photodynamique induite par rayons x, radiothérapie, chimiothérapie, immunothérapie, et toute combinaison de celles-ci - Google Patents

Nanoparticules pour thérapie photodynamique, thérapie photodynamique induite par rayons x, radiothérapie, chimiothérapie, immunothérapie, et toute combinaison de celles-ci

Info

Publication number
MA42161A
MA42161A MA042161A MA42161A MA42161A MA 42161 A MA42161 A MA 42161A MA 042161 A MA042161 A MA 042161A MA 42161 A MA42161 A MA 42161A MA 42161 A MA42161 A MA 42161A
Authority
MA
Morocco
Prior art keywords
photodynamic therapy
mof
nanoparticles
combination
immunotherapy
Prior art date
Application number
MA042161A
Other languages
English (en)
Inventor
Chunbai He
Wenbin Lin
Kuangda Lu
Original Assignee
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55747281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42161(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Chicago filed Critical Univ Chicago
Publication of MA42161A publication Critical patent/MA42161A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des structures organométalliques (mof) comprenant des photosensibilisateurs. Les mof peuvent également comprendre des fragments capables d'absorber les rayons x et / ou la scintillation. Facultativement, le photosensibilisateur ou un dérivé de celui-ci peut former un ligand de pontage du mof. En outre, facultativement, le mof peut comprendre des nanoparticules inorganiques dans les cavités ou les canaux du mof ou peut être utilisé en combinaison avec une nanoparticule inorganique. L'invention concerne également des procédés d'utilisation de mof et / ou de nanoparticules inorganiques en thérapie photodynamique ou en thérapie photodynamique induite par rayons x, avec ou sans co-administration d'un ou plusieurs agents immunothérapeutiques et / ou d'un ou plusieurs agents chimiothérapeutiques.
MA042161A 2014-10-14 2015-10-14 Nanoparticules pour thérapie photodynamique, thérapie photodynamique induite par rayons x, radiothérapie, chimiothérapie, immunothérapie, et toute combinaison de celles-ci MA42161A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462063770P 2014-10-14 2014-10-14
US201562173103P 2015-06-09 2015-06-09

Publications (1)

Publication Number Publication Date
MA42161A true MA42161A (fr) 2017-08-23

Family

ID=55747281

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042161A MA42161A (fr) 2014-10-14 2015-10-14 Nanoparticules pour thérapie photodynamique, thérapie photodynamique induite par rayons x, radiothérapie, chimiothérapie, immunothérapie, et toute combinaison de celles-ci

Country Status (6)

Country Link
US (2) US10206871B2 (fr)
EP (1) EP3206987B2 (fr)
JP (1) JP6731404B2 (fr)
CN (2) CN107001031B (fr)
MA (1) MA42161A (fr)
WO (1) WO2016061256A1 (fr)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4209510B1 (fr) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
WO2013009701A2 (fr) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Nanoparticules de métal-bisphosphonate pour thérapie anticancéreuse et imagerie, ainsi que pour traiter des troubles des os
US10034939B2 (en) * 2012-10-26 2018-07-31 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
EP3043863B1 (fr) 2013-09-11 2019-12-04 The Board of Trustees of the Leland Stanford Junior University Réseaux de structures d'accélération et imagerie rapide pour faciliter des radiothérapies rapides
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
WO2016061256A1 (fr) 2014-10-14 2016-04-21 The University Of Chicago Nanoparticules pour thérapie photodynamique, thérapie photodynamique induite par rayons x, radiothérapie, chimiothérapie, immunothérapie, et toute combinaison de celles-ci
JP6256812B2 (ja) * 2015-07-03 2018-01-10 株式会社豊田中央研究所 縮合芳香環含有ポリカルボン酸、それを用いた結晶性ネットワーク錯体及びガス吸蔵材料
US9855445B2 (en) 2016-04-01 2018-01-02 Varian Medical Systems, Inc. Radiation therapy systems and methods for delivering doses to a target volume
CN105802612A (zh) * 2016-04-28 2016-07-27 济南大学 一种检测活细胞中氧气含量的比率荧光探针的合成方法
US11246877B2 (en) 2016-05-20 2022-02-15 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
KR102747063B1 (ko) * 2016-07-21 2024-12-24 삼성전자주식회사 금속 유기 구조체를 포함하는 기능성 재료, 이의 제조 방법 및 이를 포함하는 광화학 센서
CN106518895B (zh) * 2016-09-12 2017-12-19 青岛大学 基于同时封装靶物质并合成具有氧化还原活性MOFs的制法
US20200078459A1 (en) * 2016-12-13 2020-03-12 Health Research, Inc. Near infrared (nir) photodynamic therapy (pdt) in combination with chemotherapy
CN110719783A (zh) * 2017-06-06 2020-01-21 阿特密斯株式会社 药物组合物
US10843011B2 (en) 2017-07-21 2020-11-24 Varian Medical Systems, Inc. Particle beam gun control systems and methods
US10092774B1 (en) 2017-07-21 2018-10-09 Varian Medical Systems International, AG Dose aspects of radiation therapy planning and treatment
US10549117B2 (en) 2017-07-21 2020-02-04 Varian Medical Systems, Inc Geometric aspects of radiation therapy planning and treatment
US11712579B2 (en) 2017-07-21 2023-08-01 Varian Medical Systems, Inc. Range compensators for radiation therapy
CN111479571A (zh) 2017-07-21 2020-07-31 瓦里安医疗系统公司 超高剂量率辐射和治疗剂的使用方法
US11590364B2 (en) 2017-07-21 2023-02-28 Varian Medical Systems International Ag Material inserts for radiation therapy
US10183179B1 (en) 2017-07-21 2019-01-22 Varian Medical Systems, Inc. Triggered treatment systems and methods
WO2019028250A1 (fr) * 2017-08-02 2019-02-07 The University Of Chicago Couches organométalliques nanométriques et nanoplaques organométalliques pour thérapie photodynamique induite par rayons x, radiothérapie, thérapie rodiodynamique, chimiothérapie, immunothérapie, et toute combinaison de celles-ci
CN107753946B (zh) * 2017-10-23 2020-11-27 福州大学 一种适配体修饰的靶向载药纳米粒及其制备方法与应用
CN107648606A (zh) * 2017-11-09 2018-02-02 上海纳米技术及应用国家工程研究中心有限公司 集化疗与热疗一体化核壳纳米材料的制备方法及其产品和应用
CN107652445B (zh) * 2017-11-13 2020-06-30 山东师范大学 一种a3b型单巯基卟啉修饰的金属有机框架纳米材料及其制备方法和用途
CN107641203B (zh) * 2017-11-13 2020-09-29 山东师范大学 一种a3b型单巯基卟啉化合物及其制备方法和用途
CN107828066B (zh) * 2017-11-13 2021-04-02 山东师范大学 四巯基卟啉修饰的金属有机框架纳米材料及其制备方法和用途
US11007381B2 (en) 2017-11-16 2021-05-18 Varian Medical Systems, Inc Increased beam output and dynamic field shaping for radiotherapy system
CN108037100B (zh) * 2017-11-16 2019-09-03 江南大学 一种基于FRET效应的同时检测两种miRNA的方法
CN109833478B (zh) * 2017-11-27 2021-06-01 中国科学院宁波材料技术与工程研究所 一种抗癌药物复合物及其制备方法和应用
CN108175857B (zh) * 2017-12-19 2020-10-23 中国科学院长春应用化学研究所 用于近红外光激发下具有肿瘤光动力学治疗性质的硫化铋-锌原卟啉复合材料及制法和应用
US11679372B2 (en) 2017-12-21 2023-06-20 University Of Central Florida Research Foundation, Inc. Multivariate metal-organic frameworks for fine-tuning light emission
CN109954501A (zh) * 2017-12-22 2019-07-02 中国石油化工股份有限公司 含硫化锌的碳基材料及其合成方法和应用以及环烯烃的光催化氧化方法
CN108409978B (zh) * 2018-02-28 2021-02-02 武汉大学 一种可快捷检测巯基氨基酸的金属-有机框架及其制备方法
EP3752916A1 (fr) 2018-03-12 2020-12-23 Google LLC Systèmes, procédés et appareils de gestion des actions non achevées d'un assistant automatisé
US20190314324A1 (en) 2018-04-13 2019-10-17 The University Of Chicago Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
WO2019212945A1 (fr) * 2018-05-02 2019-11-07 Memorial Sloan Kettering Cancer Center Systèmes nanothérapeutiques et méthodes utilisant une thérapie photodynamique à entraînement de particules (pdt)
CN108864118A (zh) * 2018-05-21 2018-11-23 陈聃烨 一类二苯基四氢卟吩化合物及其制备方法与应用
JP2019208422A (ja) * 2018-06-04 2019-12-12 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー ヒアルロニダーゼを含む新規な組換えエキソソーム及びその用途
CN108794757A (zh) * 2018-07-11 2018-11-13 黄河科技学院 具有大比表面积的Bodipy-二苯甲酮型COF聚合物、其制备方法及应用
US10910188B2 (en) 2018-07-25 2021-02-02 Varian Medical Systems, Inc. Radiation anode target systems and methods
CN109147049B (zh) * 2018-07-28 2022-11-01 天津大学 用于x射线光动力治疗的影像重建方法
CN110857335B (zh) * 2018-08-07 2021-06-29 中国科学院苏州纳米技术与纳米仿生研究所 二维金属-有机骨架结构纳米片及其制备方法与应用
WO2020102273A1 (fr) * 2018-11-13 2020-05-22 Northwestern University Structures organométalliques à base de bismuth destinées à être utilisées en tant qu'agents de contraste de tomodensitométrie à rayons x
GB201819853D0 (en) * 2018-12-05 2019-01-23 Innovation Ulster Ltd Therapy
CN109679110B (zh) * 2018-12-25 2020-10-09 北京科技大学 一种基于菌绿素的纳米金属-有机框架光敏剂及制备方法
US20200206144A1 (en) * 2019-01-02 2020-07-02 Lauren Lukas VanderSpek Targeted Nanoparticles for Glioblastoma Theranostics
CN109908348A (zh) * 2019-02-25 2019-06-21 浙江大学 一种制备具有光动力活性的负载亚甲基蓝的zif-90纳米粒子的方法
US11116995B2 (en) 2019-03-06 2021-09-14 Varian Medical Systems, Inc. Radiation treatment planning based on dose rate
US10814144B2 (en) 2019-03-06 2020-10-27 Varian Medical Systems, Inc. Radiation treatment based on dose rate
US11090508B2 (en) 2019-03-08 2021-08-17 Varian Medical Systems Particle Therapy Gmbh & Co. Kg System and method for biological treatment planning and decision support
US11103727B2 (en) 2019-03-08 2021-08-31 Varian Medical Systems International Ag Model based PBS optimization for flash therapy treatment planning and oncology information system
CN110003484B (zh) * 2019-03-12 2021-05-11 山东师范大学 一种装载酞菁锌的金属有机框架纳米材料及其制备方法和应用
IL265914B (en) * 2019-04-08 2020-11-30 Convergent R N R Ltd System and method for optimization of radiotherapy treatments
CN110025596A (zh) * 2019-04-25 2019-07-19 上海理工大学 一种纳米复合颗粒及其制备方法
CN110256684A (zh) * 2019-05-10 2019-09-20 深圳大学 一类四吡啶基卟啉金属-有机框架材料及制备方法和用途
CN110201160B (zh) * 2019-05-20 2021-12-03 广东医科大学 锆金属有机骨架化合物的制备方法
US10918886B2 (en) 2019-06-10 2021-02-16 Varian Medical Systems, Inc. Flash therapy treatment planning and oncology information system having dose rate prescription and dose rate mapping
CN110265670B (zh) * 2019-06-10 2021-12-21 北京化工大学 一种主客体策略合成氮、其他杂原子双掺碳基双效催化剂的方法
CN110269945A (zh) * 2019-07-10 2019-09-24 上海交通大学医学院附属第九人民医院 一种用于诊断骨关节炎的mof荧光材料及其制备方法
US11629160B2 (en) 2019-08-20 2023-04-18 University Of South Florida Corrole-based frameworks and methods of use thereof
CN110699075B (zh) * 2019-09-18 2020-12-25 广西师范大学 近红外发光的生物质量子点和对onoo-特异性响应的nir比率荧光探针及其制备方法和应用
CN110628719B (zh) * 2019-09-23 2021-08-24 山东省医学科学院基础医学研究所 一种诱导细胞快速产生囊泡的方法及其应用
US11291859B2 (en) 2019-10-03 2022-04-05 Varian Medical Systems, Inc. Radiation treatment planning for delivering high dose rates to spots in a target
CN110862546B (zh) * 2019-10-12 2021-07-09 厦门大学 一种甲氨蝶呤金属配位聚合物及其制备方法和应用
CN112755183B (zh) * 2019-11-04 2021-12-17 华中科技大学 一种有机金属框架纳米材料、其制备和应用
CN111012919B (zh) * 2019-12-23 2021-06-01 山东大学 聚乙二醇化的icd诱导剂-ido抑制剂纳米缀合物及制备方法与应用
CN111039853B (zh) * 2019-12-26 2023-02-14 安徽大学 一种可用于光声成像和光热治疗的铁配合物及其制备方法和用途
US12390662B2 (en) 2020-04-02 2025-08-19 Siemens Healthineers International Ag System and method for proton therapy treatment planning with proton energy and spot optimization
US11865361B2 (en) 2020-04-03 2024-01-09 Varian Medical Systems, Inc. System and method for scanning pattern optimization for flash therapy treatment planning
WO2021211975A1 (fr) * 2020-04-17 2021-10-21 Bioventures, Llc Nanoparticules conjuguées à un photosensibilisateur pour l'amélioration d'une radiothérapie
RU2747485C1 (ru) * 2020-05-18 2021-05-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича" (ИБМХ) Фармацевтическая композиция, включающая хлорин е6 в составе фосфолипидных наночастиц, с использованием специфического и проникающего пептидов как адресных молекул для направленного транспорта
JP2023526501A (ja) * 2020-05-22 2023-06-21 ザ・ユニバーシティ・オブ・シカゴ 金属有機構造体が癌免疫療法の為の低分子及びバイオ高分子を送達する
CN111603559B (zh) * 2020-06-05 2021-05-18 福州大学 铜碘簇化合物@光敏剂复合纳米颗粒及其作为x射线光动力治疗药物的应用
US11541252B2 (en) 2020-06-23 2023-01-03 Varian Medical Systems, Inc. Defining dose rate for pencil beam scanning
US11957934B2 (en) 2020-07-01 2024-04-16 Siemens Healthineers International Ag Methods and systems using modeling of crystalline materials for spot placement for radiation therapy
US12064645B2 (en) 2020-07-02 2024-08-20 Siemens Healthineers International Ag Methods and systems used for planning radiation treatment
CN111643673B (zh) * 2020-07-08 2022-09-13 福建医科大学孟超肝胆医院(福州市传染病医院) 一种同时包载光敏剂和蛋白质的肿瘤靶向纳米药物及其应用
WO2022009788A1 (fr) * 2020-07-08 2022-01-13 コニカミノルタ株式会社 Procédé de destruction de cellules et particules de scintillateur
US20230398112A1 (en) * 2020-08-10 2023-12-14 Research Triangle Institute Spray-dried metal-organic frameworks for treatment and/or diagnosis of pulmonary disease
CN114073922B (zh) * 2020-08-20 2024-02-20 中国科学院苏州纳米技术与纳米仿生研究所 卟啉基金属-有机骨架纳米球及其制备方法与应用
CN111999276B (zh) * 2020-08-26 2021-06-08 北京大学 一种制备发光铕基金属有机框架探针的方法及其应用
CN114225054B (zh) * 2020-09-09 2024-04-12 中国科学院宁波材料技术与工程研究所慈溪生物医学工程研究所 一种杂化有机-金属框架磁性材料作为核磁共振造影剂的应用
CN114230803A (zh) * 2020-09-09 2022-03-25 中国科学院宁波材料技术与工程研究所慈溪生物医学工程研究所 一种金属有机框架复合纳米材料及其制备方法与应用
CN112057617B (zh) * 2020-09-14 2022-06-14 中国人民解放军陆军军医大学第一附属医院 核壳结构卟啉MOFs/闪烁体复合纳米材料的制备方法及其产品和应用
CN112444510B (zh) * 2020-11-13 2022-07-08 军事科学院军事医学研究院环境医学与作业医学研究所 一种基于金属有机框架与上转换纳米颗粒的荧光检测小分子真菌毒素的方法和试剂盒
WO2022117529A1 (fr) 2020-12-01 2022-06-09 Nanobiotix Particules poreuses, à haute teneur en z et exemptes de carbone en tant que radioactivateurs
CN112546219B (zh) * 2020-12-07 2021-12-10 上海交通大学 纳米治疗结构及其制备方法
EP4011365A1 (fr) * 2020-12-09 2022-06-15 Cambridge Enterprise, Ltd. Nanoparticules mof
CN114686208B (zh) * 2020-12-31 2024-10-01 Tcl科技集团股份有限公司 一种复合试剂、防伪组合试剂及防伪方法
CN113262300B (zh) * 2021-03-29 2023-09-26 武汉科技大学 一种用于线粒体靶向递送光敏剂pcn-224的纳米粒子及制备方法、应用
CN113384696A (zh) * 2021-06-07 2021-09-14 深圳大学 一种纳米光敏剂、制备方法及其应用
CN113634240B (zh) * 2021-08-26 2023-10-27 宏葵生物（中国）股份有限公司 荧光磁性复合纳米纤维、其制备方法及应用
CN113754699B (zh) * 2021-09-08 2024-06-14 上海市质子重离子临床技术研发中心 一种铱配合物聚集体在制备放射动力学药物中的应用及制备方法
CN114163481B (zh) * 2021-12-06 2023-06-23 郑州大学 一种含铂类药物纳米囊泡及其制备方法与应用
CN114470235B (zh) * 2022-01-18 2023-05-30 山东大学 铋基金属有机框架材料在作为光控药物载体中的应用
CN114452406B (zh) * 2022-03-16 2023-05-23 安徽工程大学 一种抑菌材料及其制备方法和应用
CN115093573B (zh) * 2022-06-23 2023-06-16 中国人民解放军陆军军医大学 钽锆双金属有机框架材料及制备方法和应用
CN115386097B (zh) * 2022-08-18 2024-01-26 上海市第六人民医院 一种铪基金属有机框架材料及其制备方法和造影成像应用
CN115616056B (zh) * 2022-10-12 2025-04-25 温州医科大学 光电化学适配体传感器及其制备方法和应用
KR102891610B1 (ko) * 2022-10-17 2025-11-26 울산과학기술원 항체가 결합된 금속-유기 골격체 및 이를 포함하는 항암용 조성물
CN115873596B (zh) * 2022-11-10 2023-11-17 重庆医科大学 发光碳纳米材料及其在骨源性碱性磷酸酶检测中的应用
CN115737932B (zh) * 2022-11-23 2024-04-26 国纳之星(上海)纳米科技发展有限公司 负载x射线诱导光动力治疗/放疗协同诊疗一体化探针的骨水泥的制备及产品和应用
CN115845928B (zh) * 2022-11-30 2024-07-23 辽宁大学 一种MOFs衍生核壳结构铈基催化剂及其制备方法与应用
KR102906540B1 (ko) * 2022-12-01 2026-01-02 주식회사 메디아크 면역항암제가 탑재된 광역학 치료용 약학 조성물 및 이의 용도
KR20250149955A (ko) 2022-12-12 2025-10-17 나노비오띡스 방사선증강제로서 사용하기 위한 또는 생물학적 조직 시각화를 위한 신규한 금속 산화물 나노입자 및 이의 조성물
NO348811B1 (en) * 2023-01-06 2025-06-10 Node Pharma As MOFs with beta-emitters for radiotherapy
CN116139296B (zh) * 2023-02-27 2023-08-22 河南大学 一种具有葡萄糖响应性的山药多糖修饰的mof载药材料及其制备方法和应用
CN115945220B (zh) * 2023-03-15 2023-05-30 四川大学 一种Ir金属基生物催化剂及其制备方法和用途
CN116392607B (zh) * 2023-03-24 2025-07-11 山东师范大学 递送no并掺杂过氧化铜的纳米共价有机框架及其制备方法和应用
CN116354970B (zh) * 2023-03-28 2024-06-18 大连理工大学 一种卟啉类一氧化碳前药的制备方法及气体-声动力联合治疗应用
CN116585469A (zh) * 2023-03-30 2023-08-15 淮阴工学院 一种光敏剂@Ga-MOF抗菌微粒的制备方法及其应用
CN116041168B (zh) * 2023-04-03 2023-06-20 中国农业大学 一种金丝桃素的处理方法及获得的金丝桃素碳点和应用
CN118812426B (zh) * 2023-04-18 2025-12-12 中国科学技术大学 二价金属阳离子化合物及其制备方法和应用
EP4703323A1 (fr) * 2023-04-25 2026-03-04 Canon Kabushiki Kaisha Méthode de génération d'oxygène singulet, système de génération d'oxygène singulet, kit de génération d'oxygène singulet, et agent de génération d'oxygène singulet
CN116549718A (zh) * 2023-05-12 2023-08-08 上海交通大学医学院附属第九人民医院 用于感染性创面的水凝胶敷料，其制备方法及水凝胶墨水
CN117138055B (zh) * 2023-06-02 2024-04-16 中山大学附属第一医院 一种双载体的阿霉素载药纳米材料及其制备方法
CN116425995B (zh) * 2023-06-12 2023-10-20 吉林省卓材新研科技有限公司 一种金属有机框架材料及其配体和应用
WO2025010407A2 (fr) * 2023-07-05 2025-01-09 The University Of Chicago Structures organométalliques à échelle nanométrique avec promédicaments déclenchables par rayons x pour radiothérapie, chimiothérapie et immunothérapie combinées
CN116920121A (zh) * 2023-07-21 2023-10-24 中国药科大学 一种纳米级金属有机配位聚合物及其制备方法和应用
CN117534711A (zh) * 2023-09-28 2024-02-09 深圳大学 近红外光动力敏化剂铂配合物的合成与在制药领域的应用
WO2025125384A1 (fr) 2023-12-11 2025-06-19 Cambridge Enterprise Limited Compositions d'hydrogel
WO2025125382A1 (fr) 2023-12-11 2025-06-19 Cambridge Enterprise Limited Nanoparticules mof
CN117701025B (zh) * 2023-12-14 2025-09-30 大连理工大学宁波研究院 尼罗蓝-parp抑制剂染料及其合成方法与应用
CN120093918B (zh) * 2025-05-07 2025-07-25 三峡大学 一种近红外光敏剂bopyin在制备治疗肿瘤的药物中的用途
CN120478634B (zh) * 2025-07-18 2025-09-19 吉林大学 金属／醌纳米粒子声敏剂及其制备方法和应用
CN121270877B (zh) * 2025-12-10 2026-03-13 山东第二医科大学附属医院 一种抑制π-π堆积效应的大环共价有机聚合物材料及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61351A (en) 1980-10-27 1983-12-30 Yeda Res & Dev Organometallic polymers,their preparation and compositions of co-ordination compounds containing them
US5147806A (en) 1988-04-29 1992-09-15 Igen, Inc. Method and apparatus for conducting electrochemiluminescence measurements
US5213788A (en) 1988-09-29 1993-05-25 Ranney David F Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
JP2611073B2 (ja) 1990-07-26 1997-05-21 モンサント カンパニー 新規ポリアミンの製造方法
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5871710A (en) 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5641623A (en) 1995-01-04 1997-06-24 Martin; Mark T. Electrochemiluminescence assay
US20010003647A1 (en) 1995-06-07 2001-06-14 Ji Sun Coreatant-including electrochemiluminescent compounds, methods, systems and kits utilizing same
US6022737A (en) 1995-11-02 2000-02-08 Amgen Inc. Formulations for non-viral in vivo transfection in the lungs
US5648508A (en) 1995-11-22 1997-07-15 Nalco Chemical Company Crystalline metal-organic microporous materials
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6180082B1 (en) 1997-11-24 2001-01-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method to enhance tissue accumulation of radiolabeled compounds
US6818227B1 (en) 1999-02-08 2004-11-16 Alza Corporation Liposome composition and method for administration of a radiosensitizer
US6602932B2 (en) 1999-12-15 2003-08-05 North Carolina State University Nanoparticle composites and nanocapsules for guest encapsulation and methods for synthesizing same
US6530944B2 (en) 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US6548264B1 (en) 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
EP1383775B1 (fr) 2001-04-30 2006-08-02 The Regents of The University of Michigan Structures organometalliques isoreticulaires, procede d'obtention, et conception systematique du calibre des pores et fonctionnalites integrees, avec application pour le stockage des gaz
WO2003094767A1 (fr) 2002-03-25 2003-11-20 The General Hospital Corporation Therapie photodynamique et radiotherapie adjuvantes
KR100401335B1 (en) 2003-03-08 2003-10-10 Mijitech Co Ltd Metal nanoparticle surface-coated with silicon oxides and preparation thereof
KR20050115315A (ko) 2003-03-26 2005-12-07 가부시키가이샤 엘티티 바이오파마 약물 전달 및 서방성 약물 방출을 표적으로 하는 정맥 내 나노입자
CA2524903A1 (fr) * 2003-05-09 2004-11-25 The Regents Of The University Of Michigan Mise en oeuvre d'une strategie visant a obtenir des niveaux extraordinaires de superficie et de porosite dans des cristaux
KR20060054371A (ko) 2003-07-31 2006-05-22 쓰리엠 이노베이티브 프로퍼티즈 컴파니 캡슐화 및 제어된 방출을 위한 조성물
WO2005048942A2 (fr) 2003-11-13 2005-06-02 Pharmacia Corporation Polytherapie contenant un inhibiteur cox-2 et un agent antineoplasique
US20050147963A1 (en) 2003-12-29 2005-07-07 Intel Corporation Composite organic-inorganic nanoparticles and methods for use thereof
US7430282B2 (en) 2004-03-29 2008-09-30 National Institute Of Radiological Sciences Heel effect compensation filter X-ray irradiator, X-ray CT scanner and method for X-ray CT imaging
US20070259966A1 (en) 2004-04-22 2007-11-08 Allos Therapeutics, Inc. Coadministration of Radiation, Efaproxiral Sodium, and Supplemental Oxygen for the Treatment of Cancer
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US20070218049A1 (en) * 2006-02-02 2007-09-20 Wei Chen Nanoparticle based photodynamic therapy and methods of making and using same
CN1305937C (zh) 2005-02-25 2007-03-21 复旦大学 一种金属配位聚合物纳米结构材料的制备方法
US7263170B2 (en) 2005-09-30 2007-08-28 Pellegrino Anthony J Radiation therapy system featuring rotatable filter assembly
GB0524439D0 (en) 2005-12-01 2006-01-11 Delphi Tech Inc Jet pump apparatus for a vehicle fuel tank
US20090242856A1 (en) 2006-02-09 2009-10-01 Simon Fraser University Birefringent metal-containing coordination polymers
US20100189222A1 (en) 2006-02-16 2010-07-29 Steller Micro Devices Panoramic irradiation system using flat panel x-ray sources
KR100943923B1 (ko) 2006-03-17 2010-02-24 홍순해 킬레이팅 유기 고분자와 생물학적 금속으로 이루어진 나노입자, 그리고 ｅｐｒ 효과를 이용한 새로운 광범위 무독성항암제 및 그 제조 방법
US7985868B1 (en) 2006-11-01 2011-07-26 Sandia Corporation Hybrid metal organic scintillator materials system and particle detector
US20080124281A1 (en) 2006-11-29 2008-05-29 Board Of Regents, The University Of Texas System Nanotubular probes as ultrasensitive mr contrast agent
WO2008102632A1 (fr) 2007-02-21 2008-08-28 Konica Minolta Medical & Graphic, Inc. Filtre passe-bande de rayons x, système d'irradiation de rayons x et système de radiographie
JP5730574B2 (ja) 2007-09-25 2015-06-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 食用に適した生体適合性金属有機構造体
WO2009139939A2 (fr) 2008-02-22 2009-11-19 The University Of North Carolina At Chapel Hill Nanoparticules hybrides comme agents thérapeutiques anticancéreux et agents doubles thérapeutiques/de contraste d’imagerie
EP2445532A1 (fr) 2009-04-24 2012-05-02 Socpra - Sciences Santé Et Humaines Compositions comprenant un radiosensibilisant et un agent anticancéreux et leurs procédés d'utilisation
EP2445534A2 (fr) * 2009-05-25 2012-05-02 Merck Patent GmbH Administration continue du cilengitide dans des traitements du cancer
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
WO2011049743A1 (fr) 2009-10-06 2011-04-28 Stellarray, Inc. Système d'irradiation autonome utilisant des sources de rayons x pour écran plat
WO2012138419A1 (fr) 2011-04-04 2012-10-11 Georgia Tech Research Corporation Nanocristaux de mof
EP2721032A4 (fr) 2011-06-16 2014-11-05 Univ South Florida Structures métalloporphyrines contenant une cage polyédrique, procédés de fabrication et d'utilisation
WO2013009701A2 (fr) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Nanoparticules de métal-bisphosphonate pour thérapie anticancéreuse et imagerie, ainsi que pour traiter des troubles des os
US9517277B2 (en) 2011-07-15 2016-12-13 University Of Georgia Research Foundation, Inc. Immune-stimulating photoactive hybrid nanoparticles
HK1203353A1 (en) 2011-12-16 2015-10-30 Nanobiotix Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof
WO2013188763A1 (fr) * 2012-06-15 2013-12-19 The Brigham And Women's Hospital, Inc. Compositions pour le traitement du cancer et leurs procédés de préparation
HRP20190628T1 (hr) * 2013-01-11 2019-06-14 Dingfu Biotarget Co., Ltd Sredstva za liječenje tumora, njihova uporaba i postupak iste
US10350275B2 (en) 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
CN105873569B (zh) 2013-11-06 2020-07-28 芝加哥大学 用于化疗剂、核酸和光敏剂的递送或共递送的纳米级载体
US10647733B2 (en) 2014-03-28 2020-05-12 The University Of Chicago Metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations
WO2015149068A1 (fr) 2014-03-28 2015-10-01 The University Of Chicago Réseaux métallo-organiques basés sur un ligand chiral pour catalyse asymétrique à large portée
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
WO2016061256A1 (fr) 2014-10-14 2016-04-21 The University Of Chicago Nanoparticules pour thérapie photodynamique, thérapie photodynamique induite par rayons x, radiothérapie, chimiothérapie, immunothérapie, et toute combinaison de celles-ci

Also Published As

Publication number Publication date
CN107001031A (zh) 2017-08-01
US10780045B2 (en) 2020-09-22
CN107001031B (zh) 2019-11-15
JP2017532340A (ja) 2017-11-02
JP6731404B2 (ja) 2020-07-29
CN110731961A (zh) 2020-01-31
EP3206987B2 (fr) 2024-07-24
EP3206987B1 (fr) 2020-07-01
EP3206987A4 (fr) 2018-03-28
US20190209460A1 (en) 2019-07-11
EP3206987A1 (fr) 2017-08-23
US10206871B2 (en) 2019-02-19
WO2016061256A1 (fr) 2016-04-21
US20170231903A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
TN2019000040A1 (en) Anti-tim-3 antibodies
PH12019501253A1 (en) Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
WO2016055432A3 (fr) Traitement combiné d'anticorps bispécifiques spécifiques de fap et dr5 et agents chimiothérapeutiques
MX2024015039A (es) Composiciones anti-cd24 y usos de las mismas
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
MX2017013613A (es) Neoepitodos de cancer.
PH12020500225A1 (en) Anti- cd137 antibodies
CY1121723T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
WO2014176475A3 (fr) Inhibiteurs des egfr et leurs utilisations
MX388015B (es) Un anticuerpo anti-csf1r y al menos un agente inmuno-estimulador para usarse en el tratamiento de cáncer.
MX392539B (es) Combinaciones de inmunoconjugado anti-cd37 y anticuerpo anti-cd20.
WO2015153514A8 (fr) Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40
WO2015067570A3 (fr) Combinaisons pharmaceutiques comprenant des anticorps cd33 et des agents de déméthylation
EP3206987A4 (fr) Nanoparticules pour thérapie photodynamique, thérapie photodynamique induite par rayons x, radiothérapie, chimiothérapie, immunothérapie, et toute combinaison de celles-ci
WO2017136659A3 (fr) Anticorps humanisés anti-cd3, conjugués et leurs utilisations
MX2016009717A (es) Agentes citotoxicos bifuncionales.
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
WO2018156502A3 (fr) Gels activés par rayonnement et libérant des fluides et ensembles les contenant
HK1222340A1 (zh) 抗folr1免疫缀合物给药方案
WO2015031815A3 (fr) Anticorps et dosages pour la détection du récepteur 1 du folate
EP4424323A3 (fr) Schémas posologiques d'immunoconjugués anti-folr1
WO2016100738A3 (fr) Activité antifibrotique d'inhibiteur de gas6
EA201792058A1 (ru) Виротерапия комбинацией антител
MX2011012491A (es) Administracion continua de cilengitida en tratamientos contra el cancer.
WO2011127388A3 (fr) Agonistes inverses et antagonistes neutres pour récepteur du tsh